Literature DB >> 18155020

A strategy for bacterial production of a soluble functional human neonatal Fc receptor.

Jan Terje Andersen1, Sune Justesen, Gøril Berntzen, Terje E Michaelsen, Vigdis Lauvrak, Burkhard Fleckenstein, Søren Buus, Inger Sandlie.   

Abstract

The major histocompatibility complex (MHC) class I related receptor, the neonatal Fc receptor (FcRn), rescues immunoglobulin G (IgG) and albumin from lysosomal degradation by recycling in endothelial cells. FcRn also contributes to passive immunity by mediating transport of IgG from mother to fetus (human) or newborn (rodents), and may translocate IgG over mucosal surfaces. FcRn interacts with the Fc-region of IgG and domain III of albumin with binding at pH 6.0 and release at pH 7.4. Knowledge of these interactions has facilitated design of recombinant proteins with altered serum half-lives and/or altered biodistribution. To generate further research in this field, there is a great need for large amounts of soluble human FcRn (shFcRn) for in vitro interaction studies. In this report, we describe a novel laboratory scale production of functional shFcRn in Escherichia coli (E. coli) at milligram level. Truncated wild type hFcRn heavy chains were expressed, extracted, purified from inclusion bodies under denaturing non-reducing conditions, and subsequently refolded in the presence of human beta(2)-microglobulin (hbeta(2)m). The secondary structural elements of refolded heterodimeric shFcRn were correctly formed as demonstrated by circular dichroism (CD). Furthermore, functional and stringent pH dependent binding to IgG and human serum albumin were demonstrated by ELISA and surface plasmon resonance (SPR). This method may be easily adapted for the expression of large amounts of other FcRn species and MHC class I related molecules.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155020     DOI: 10.1016/j.jim.2007.11.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  11 in total

Review 1.  Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn.

Authors:  Kristi Baker; Shuo-Wang Qiao; Timothy Kuo; Kanna Kobayashi; Masaru Yoshida; Wayne I Lencer; Richard S Blumberg
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

Review 2.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Authors:  Alina Sesarman; Gestur Vidarsson; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-03-09       Impact factor: 9.261

3.  A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.

Authors:  Paul J Yazaki; Brian Lee; Divya Channappa; Chia-Wei Cheung; Desiree Crow; Junie Chea; Erasmus Poku; Lin Li; Jan Terje Andersen; Inger Sandlie; Kelly Davis Orcutt; K Dane Wittrup; John E Shively; Andrew Raubitschek; David Colcher
Journal:  Protein Eng Des Sel       Date:  2012-11-21       Impact factor: 1.650

4.  Characterization and screening of IgG binding to the neonatal Fc receptor.

Authors:  Tobias Neuber; Katrin Frese; Jan Jaehrling; Sebastian Jäger; Daniela Daubert; Karin Felderer; Mechthild Linnemann; Anne Höhne; Stefan Kaden; Johanna Kölln; Thomas Tiller; Bodo Brocks; Ralf Ostendorp; Stefan Pabst
Journal:  MAbs       Date:  2014-04-07       Impact factor: 5.857

5.  Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.

Authors:  Yang Feng; Rui Gong; Dimiter S Dimitrov
Journal:  Protein Expr Purif       Date:  2011-03-29       Impact factor: 1.650

Review 6.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

7.  Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential.

Authors:  Nigel M Stapleton; Jan Terje Andersen; Annette M Stemerding; Stefania P Bjarnarson; Ruurd C Verheul; Jacoline Gerritsen; Yixian Zhao; Marion Kleijer; Inger Sandlie; Masja de Haas; Ingileif Jonsdottir; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Nat Commun       Date:  2011-12-20       Impact factor: 14.919

8.  MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides.

Authors:  Peter Braendstrup; Sune Justesen; Thomas Osterbye; Lise Lotte Bruun Nielsen; Roberto Mallone; Lars Vindeløv; Anette Stryhn; Søren Buus
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

9.  Selection of nanobodies that target human neonatal Fc receptor.

Authors:  Jan Terje Andersen; Maria Gonzalez-Pajuelo; Stian Foss; Ole J B Landsverk; Débora Pinto; Alexander Szyroki; Hans J de Haard; Michael Saunders; Peter Vanlandschoot; Inger Sandlie
Journal:  Sci Rep       Date:  2013-01-23       Impact factor: 4.379

10.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays.

Authors:  Sune Justesen; Mikkel Harndahl; Kasper Lamberth; Lise-Lotte B Nielsen; Søren Buus
Journal:  Immunome Res       Date:  2009-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.